EXAC News Alert Exactech Inc (EXAC) 22.68 12/25/2014 11:31:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Exactech Inc (EXAC) 22.68 $EXAC

Exactech's Equinoxe Shoulder System: 10 Years of Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:55PM CST
Developer of orthopedic implant devices Exactech Inc. (EXAC) recently announced the 10th year anniversary of its Equinoxe Shoulder System, a product line in its shoulder business.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)

Industry's Fastest Growing Shoulder System Marks 10 Years of Improving Patient Outcomes
Business Wire - Mon Nov 17, 7:08AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, this week recognizes the 10th anniversary of its unique Equinoxe(R) Shoulder System.
EXAC: 22.68 (+0.24)

Exactech's (EXAC) Octane Elevate to Advance Spine Surgery - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:15PM CST
Developer of orthopedic implant devices, Exactech Inc. (EXAC), recently announced the launch of Octane Elevate, a self-distracting lumber fusion device made of Poly Ether Ether Ketone (PEEK), a colorless organic thermoplastic polymer.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)

Globus Medical to Redefine Spinal Fusion with ALTERA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:07PM CST
Manufacturer of musculoskeletal implants, Globus Medical Inc. (GMED), recently announced the launch of ALTERA, which is claimed to be the first minimally intrusive expandable spacer.
ZMH: 114.11 (+0.64), GMED: 24.37 (+0.44), EXAC: 22.68 (+0.24), SYK: 96.00 (-0.61)

Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 83.38 (+1.63), BABY: 36.45 (+1.14), EXAC: 22.68 (+0.24), IDXX: 148.68 (+1.45)

Exactech Offers High Growth And Trades At A Discount To Fair Value
Jonathan Weber - at Seeking Alpha - Wed Nov 12, 12:16PM CST

EXAC: 22.68 (+0.24)

Exactech Launches Octane(R) Elevate Peek Spacer System For Lumbar Interbody Fusion Procedures
Business Wire - Tue Nov 11, 6:56AM CST
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announces that its spine division has launched Octane(R) Elevate, a Poly Ether Ether Ketone (PEEK) spacer system, at the North American Spine Society Annual Meeting (NASS).
EXAC: 22.68 (+0.24)

Exactech Shares Down 10.1% Since SmarTrend's Sell Call (EXAC)
Comtex SmarTrend(R) - Thu Oct 30, 11:08AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 4 months, Exactech has returned 10.14% as of today's recent price of $21.36.
EXAC: 22.68 (+0.24)

Organ and Tissue Transplantation Markets - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zx4hg8/organ_and_tissue) has announced the addition of the "Organ and Tissue Transplantation - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs) The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: - Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine) - Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), - Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report profiles 24 companies including many key and niche players such as: - CryoLife, Inc - Exactech, Inc - Folio Biosciences - K?hler Chemie - LifeCell Corporation - Medtronic, Inc. - Organogenesis, Inc. - Organ Recovery Systems - Organ Transport Systems - XVIVO Perfusion AB Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET TRENDS 3. TECHNOLOGICAL INNOVATIONS 4. MAJOR ISSUES IMPACTING TRANSPLANTATION MARKET 5. PRODUCT OVERVIEW 6. ARTIFICIAL ORGANS - AN ALTERNATIVE TO SOLID ORGAN TRANSPLANTS 7. PRESERVATION SOLUTIONS & IMMUNOSUPPRESSANT DRUGS 8. REGULATORY ENVIRONMENT 9. PRODUCT DEVELOPMENT/INNOVATIONS 10. RECENT INDUSTRY ACTIVITY 11. FOCUS ON SELECT GLOBAL PLAYERS 12. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 24 - The United States (21) - Europe (2) - - Germany (1) - - Rest of Europe (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/zx...and_tissue
MDT: 74.08 (+0.31), EXAC: 22.68 (+0.24), CRY: 11.53 (+0.38)

Global Organ and Tissue Transplantation Market
PR Newswire - Thu Oct 23, 4:35PM CDT
This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report are analyzed by the following Product Segments - Organ Tranplantation (Heart, Kidneys, Liver, Pancreas, and Lungs). The US market for 'Organ and Tissue Transplantation' in this report is analyzed by the following Product Segments: Organ Type (Heart, Kidneys, Liver, Pancreas, Lungs, and Intestine), Tissue Type (Cornea, Heart Valve, Skin Grafts, Vascular Grafts, Bone Marrow, and Bone Grafts), and Bone Graft Transplantation (By Graft Type: Autologous Graft, Allograft, and Other Materials; By Application Type: General Orthopedics, Spinal Fusions, and Cranio/Maxillofacial). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -
EXAC: 22.68 (+0.24), CRY: 11.53 (+0.38)

Exactech's (EXAC) CEO David Petty on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 2:57PM CDT

EXAC: 22.68 (+0.24)

Exactech posts 3Q profit
Automated Insights - Tue Oct 21, 3:28PM CDT
GAINSVILLE, Fla. (AP) _ Exactech Inc. (EXAC) on Tuesday reported net income of $3 million, or 21 cents per share, in its third quarter.
EXAC: 22.68 (+0.24)

Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23
Business Wire - Tue Oct 21, 3:00PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today revenue of $57.9 million for the third quarter of 2014, a 4% increase over $55.7 million in the third quarter of 2013. Net income was $3.0 million, or $0.21 per diluted share, compared to $3.2 million, or $0.23 per diluted share, in the same quarter a year ago.
EXAC: 22.68 (+0.24)

Shares of EXAC Down 15.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 16, 9:33AM CDT
SmarTrend identified a Downtrend for Exactech (NASDAQ:EXAC) on July 17th, 2014 at $23.77. In approximately 3 months, Exactech has returned 15.72% as of today's recent price of $20.03.
EXAC: 22.68 (+0.24)

Nasdaq stocks posting largest volume increases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CHFN: 11.36 (-0.07), ARTW: 4.97 (+0.02), PPHM: 1.40 (+0.01), PENX: 18.83 (+0.04), LAKE: 8.94 (+0.07), EXAC: 22.68 (+0.24), NAUH: 2.93 (+0.11), COVS: 2.73 (+0.08), UPIP: 1.05 (+0.03), JAXB: 12.26 (+0.96), CEMI: 3.98 (+0.08), DENN: 9.96 (+0.05)

Nasdaq stocks posting largest percentage decreases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
IMDZ: 34.96 (+0.78), CENT: 8.66 (+0.06), AXDX: 18.47 (+0.03), KTCC: 7.99 (unch), CENTA: 9.30 (+0.06), EXAC: 22.68 (+0.24), LAKE: 8.94 (+0.07), MTEX: 28.96 (unch), IKNX: 15.00 (-0.19)

Best U.S. Stock Ideas Today
Aviate - Seeking Alpha - Wed Oct 15, 8:52AM CDT
1. United Rentals: cover short and revisit post earnings 2. Citi: Discount to peers on a TBV buy case still intact 3. Intel: Microchip should have said it’s me not you 4. Europe FX headwinds persist 5. Technicals 6. Trader...
UTX: 116.91 (-0.30), C: 54.54 (+0.12), RBS: 12.31 (+0.14), CA: 31.31 (-0.02), INTC: 37.44 (+0.01), EXAC: 22.68 (+0.24), EMC: 30.69 (+0.14), URI: 104.84 (+0.16), FDX: 176.42 (-0.52), KO: 42.94 (-0.03), BUD: 115.51 (+0.09), HAR: 105.30 (+0.11), SWKS: 74.32 (+0.92), HSON: 3.01 (+0.01), DTE: 87.94 (+1.53), ITW: 97.11 (-0.10), SO: 49.91 (+0.74), PCLN: 1,149.78 (+2.17), ASML: 109.64 (+0.51), DISH: 72.63 (+0.54), BWA: 55.67 (-0.72), PH: 130.85 (-0.21), FLR: 60.30 (-0.26), ADSK: 60.99 (+0.34), JCI: 48.50 (-0.23)

Exactech Schedules Q3 2014 Earnings Release and Conference Call
Business Wire - Mon Oct 13, 3:50PM CDT
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its third quarter 2014 financial results on Tuesday, October 21st, 2014. A copy of the earnings release will be available at http://www.hawkassociates.com.
EXAC: 22.68 (+0.24)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading

Top 5 Most Recently Viewed Articles

GoldHaven Resources Expands Exploration Amid Robust Gold Prices

Updated Category News Views 299

Gold's Resilience Fuels Growth Initiatives Gold prices have steadily stabilized above $4,200 per ounce, prompting renewed interest among investors seeking safe-haven assets. This robust price environment encourages extensive drilling programs aimed at expanding resource bases. GoldHaven Resources Corp. (CSE: GOH) is at the forefront of this momentum, actively advancing...

Continue Reading
HSBC Highlights Reliance Industries' Growth Potential and Strategy

Updated Category News Views 287

HSBC Upgrades Reliance Industries Stock Target Recently, HSBC raised its price target for Reliance Industries (RIL:IN) from INR 2,780.00 to INR 3,010.00 while maintaining a Hold rating. This revision reflects a promising outlook on the company's comprehensive business structure and financial standing. Core Sectors Driving Performance HSBC's analysts highlighted Reliance's...

Continue Reading
Vallourec's Strategic Move: Partial Redemption of Notes

Updated Category News Views 142

Vallourec's Strategic Financial Maneuver Vallourec, an industry leader in premium tubular solutions, has made a significant announcement regarding its senior notes due 2032. This decision is part of its ongoing strategy to enhance its financial stability and market position. Details of the Partial Redemption The company plans to redeem $82 million of its senior notes,...

Continue Reading
Health Assurance Foundation Teams Up to Enhance Healthcare Access

Updated Category News Views 80

The Health Assurance Foundation officially launched as a nonprofit back in 2024, focusing on strengthening the healthcare system by investing in local communities. Its mission? Making healthcare more equitable and accessible for everyone. Sounds good on paper, right? But when you peel back the layers, things get murky. Community Health Worker Initiative: Is It Enough? The...

Continue Reading
Market Pay Unveils Seamless POS Solution for Merchants Across Europe

Updated Category News Views 208

Market Pay Launches a Game-Changing Payment Solution The French fintech company Market Pay, a prominent player in the European payment processing field, is excited to unveil its new point-of-sale software payment solution. This innovative app integrates both terminal and smartphone payment options into a single, user-friendly platform. This development not only simplifies...

Continue Reading